CA-SOLIDIGM
16.5.2023 16:01:29 CEST | Business Wire | Press release
Solidigm, a leading global provider of innovative NAND flash memory solutions, is expanding its D5 Product Series with the Solidigm™ D5-P5430, a new QLC solid-state storage drive (SSD) optimized for mainstream and read-intensive workloads.
With most of today’s enterprise applications read-dominant, the D5-P5430 — a 4th gen PCIe QLC SSD — offers substantial storage density and Total Cost of Ownership (TCO) opportunities while delivering read performance that is equivalent to the most widely-adopted TLC SSDs.
The D5-P5430 is optimized for mainstream workloads (e.g., email/unified communications, decision support systems, object storage, and virtual desktop infrastructure) and read-intensive workloads (e.g., content delivery networks, data lakes/pipelines, video-on-demand). These workloads are typically 80% reads or higher and need to move massive amounts of data at high throughput.
As a drop-in replacement for TLC NAND-based PCIe-based SSDs, the D5-P5430 can reduce TCO by up to 27% for a typical object storage solution with a 1.5X increase in storage density and 18% lower energy cost. In addition, Solidigm’s newest drive can deliver up to 14% higher lifetime writes vs. leading TLC SSDs.
Important data center issues like power efficiency, edge computing, and sustainability of infrastructure, all benefit from the density of the D5-P5430, which can reduce power and cooling costs and lower the number of drives needed by up to 2x when compared to alternative solutions.
“Data centers need to store and analyze massive amounts of data with cost-effective and sustainable solutions,” said Greg Matson, VP, Strategic Planning and Marketing, Solidigm. “Solidigm’s D5-P5430 drives are ideal for this purpose, delivering high density, reduced TCO, and ‘just right’ performance for mainstream and read-intensive workloads.”
The D5-P5430 supports a wide range of 1U and 2U server and storage configurations with a broad range of capacities that support the following legacy and modern EDSFF form factors:
- U.2 15mm 3.84 TB – 30.72 TB*
- E1.S 9.5mm 3.84 TB – 15.36 TB
- E3.S 7.5 mm 3.84 TB – 30.72 TB*
“Supermicro works with leading storage suppliers like Solidigm to bring the latest technology to our global customers that expect high-performance and secure storage technology,” said Vik Malyala, Managing Director and President, EMEA; SVP, WW FAE, Supermicro. “Solidigm’s new QLC-based E3.S SSD, the D5-P5430, gives customers a compelling combination of high density and efficiency for the data center infrastructure.”
*30 TB versions will be available later this year
ABOUT SOLIDIGM
Solidigm is a leading global provider of innovative NAND flash memory solutions. Solidigm technology unlocks data’s unlimited potential for customers, enabling them to fuel human advancement. Originating from the sale of Intel’s NAND and SSD business, Solidigm became a standalone U.S. subsidiary of semiconductor leader SK hynix in December 2021. Headquartered in Rancho Cordova, California, Solidigm is powered by the inventiveness of more than 2,000 employees in 13 locations worldwide. For more information, please visit solidigm.com and follow us on Twitter and LinkedIn. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp. (d/b/a Solidigm).
- All products, computer systems, dates, and figures specified are preliminary based on current expectations and are subject to change without notice.
- Differences in hardware, software, or configuration will affect actual performance.
- Solidigm optimizations, for Solidigm compilers or other products may not optimize to the same degree for non-Solidigm products.
- Solidigm technologies may require enabled hardware, software, or service activation.
- Nothing herein is intended to create any express or implied warranty.
- The products described in this document may contain design defects or errors known as “errata,” which may cause the product to deviate from published specifications. Currently characterized errata are available on request.
- Your costs and results may vary.
- © Solidigm. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp. (d/b/a Solidigm). Other names and brands may be claimed as the property of others.
To learn more about Solidigm™ D5-5430 and the benefits of QLC, visit solidigm.com/qlc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005023/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 08:00:00 CEST | Press release
Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1Median time-to-next-treatment(TTNT), the study's primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, folliculotropic mycosis fungoides and mogamulizumab-associated rash status, supporting individualised treatment for patients with mycosis fungoides and Sézary syndrome1 Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous
Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 08:00:00 CEST | Press release
Megaport’s expansion to Portugal unlocks access to compute, network, and storage services for the local and global markets. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural
Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 18:09:00 CEST | Press release
Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,
Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 12:30:00 CEST | Press release
As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom